Axsome Therapeutics, Inc.
AXSMHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeAxsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. At a $7.60B market cap, Axsome Therapeutics, Inc. ranks as a mid-cap company within healthcare. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Market Cap
$7.60B
Beta
0.85
P/E (TTM)
—
P/E (Fwd)
39.27
EPS (TTM)
$-3.74
EPS (Fwd)
$3.69
ROE
-245.1%
ROA
-16.3%
Cash
$319.8M
Total Debt
$224.7M
Free CF
-$4.6M
52W Change
7.7%
Annual Financials
Cash vs Debt
Where AXSM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AXSM finished 25.36% below its 150-day moving average ($208.76) and 22.27% below its 200-day moving average ($200.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AXSM overbought or oversold?
At the October 20, 2026 close, AXSM's RSI(14) was 14.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $319.8M in cash comfortably exceeding the $224.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$4.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -245.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $50.0M (2022) to $638.5M (2025), reflecting a 1176% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing AXSM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.